A nomogram based on tumor response to induction chemotherapy may predict survival in locoregionally advanced nasopharyngeal carcinoma. Issue 6 (25th February 2022)

• Record Type: Journal Article
• Authors: Jiang, Yu‐Ting; Chen, Kai‐Hua; Liang, Zhong‐Guo; Yang, Jie; Wei, Si‐Qi; Qu, Song; Li, Ling; Zhu, Xiao‐Dong
• Is Part Of: Head & neck. Volume 44:Issue 6(2022)
• Page Start: 1301
• Page End: 1312
• Publication Date: 2022-02-25
• Subjects: induction chemotherapy -- nasopharyngeal carcinoma -- nomogram -- survival -- tumor response; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.27020
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: To evaluate the clinical significance of tumor response to induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients and further to develop a nomogram for predicting survival prognosis. Methods: A total of 498 patients with stage III‐IVA NPC applying IC and concurrent chemotherapy were reviewed (training cohort, n = 376; validation cohort, n = 122). Results: Tumor response was an independent predictor for clinical outcomes. The nomogram included age, N stage, pretreatment Epstein–Barr virus DNA, lymphocyte‐to‐monocyte ratio, and tumor response achieved an ideal C‐index of 0.703 (95% CI 0.655–0.751) in the validation cohort for predicting overall survival (OS), which outperformed than that of the TNM system alone (C‐index, 0.670, 95% CI: 0.622–0.718). In addition, the nomogram could successfully classified patients into different risk groups. Conclusions: We established and validated a precise and convenient nomogram based on tumor response for predicting the OS of LANPC patients.